RNXT vs. IPHA, SCPH, DRUG, SOPH, ACTU, BTMD, INBX, KOD, ESPR, and TIL
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Innate Pharma (IPHA), scPharmaceuticals (SCPH), Bright Minds Biosciences (DRUG), SOPHiA GENETICS (SOPH), Actuate Therapeutics (ACTU), biote (BTMD), Inhibrx (INBX), Kodiak Sciences (KOD), Esperion Therapeutics (ESPR), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.
RenovoRx vs. Its Competitors
RenovoRx (NASDAQ:RNXT) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
RenovoRx currently has a consensus target price of $7.25, suggesting a potential upside of 433.09%. Innate Pharma has a consensus target price of $11.00, suggesting a potential upside of 455.56%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than RenovoRx.
Innate Pharma received 34 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 60.00% of users gave Innate Pharma an outperform vote while only 56.00% of users gave RenovoRx an outperform vote.
3.1% of RenovoRx shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 9.1% of RenovoRx shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Innate Pharma's return on equity of 0.00% beat RenovoRx's return on equity.
RenovoRx has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.
In the previous week, RenovoRx had 6 more articles in the media than Innate Pharma. MarketBeat recorded 8 mentions for RenovoRx and 2 mentions for Innate Pharma. RenovoRx's average media sentiment score of 1.14 beat Innate Pharma's score of 0.93 indicating that RenovoRx is being referred to more favorably in the media.
Innate Pharma has higher revenue and earnings than RenovoRx.
Summary
Innate Pharma beats RenovoRx on 10 of the 16 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
This page (NASDAQ:RNXT) was last updated on 6/13/2025 by MarketBeat.com Staff
